Nuvation Bio Launches Access Program for Taletrectinib in ROS1-Positive Lung Cancer Patients

Nuvation Bio Launches Expanded Access Program for Taletrectinib in ROS1-Positive NSCLC

Nuvation Bio Inc., a biopharmaceutical company committed to addressing crucial unmet needs in oncology, announces the launch of an Expanded Access Program (EAP) for taletrectinib, specifically targeting patients in the U.S. with locally advanced or metastatic ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). This initiative aims to provide access to taletrectinib for patients who have limited or no satisfactory alternative therapies available. Dr. David Hung, the company’s Founder and CEO, underscores Nuvation Bio’s commitment to the ROS1-positive NSCLC community, emphasizing the importance of facilitating access to potentially life-saving treatments outside of traditional clinical trial settings.

The Expanded Access Program, authorized by the U.S. Food and Drug Administration (FDA), is particularly significant for patients suffering from serious cases of ROS1+ NSCLC who may not qualify for ongoing pivotal Phase 2 studies. The launch of this program reflects Nuvation Bio's proactive approach to patient care, addressing the urgent need for therapeutic options in a patient population that traditionally faces unique challenges. Janet Freeman-Daily, Co-Founder of The ROS1ders, a patient advocacy group, highlights the critical role of Expanded Access Programs in allowing patients to access investigational drugs, especially when existing approved therapies prove inadequate.

Further reinforcing its dedication to the ROS1-positive NSCLC community, Nuvation Bio has also taken steps towards formal regulatory approval of taletrectinib. In December 2024, the FDA accepted the company’s New Drug Application (NDA) for taletrectinib, designating it with Priority Review status and establishing a Prescription Drug User Fee Act (PDUFA) goal date of June 23, 2025. The NDA is bolstered by results from the TRUST-I and TRUST-II studies, which were presented at the European Society of Medical Oncology (ESMO) Congress in September 2024. As the EAP facilitates access for patients deemed ineligible for approved therapies or ongoing clinical studies, it highlights Nuvation Bio's commitment to improving patient outcomes in this underserved area of oncology.

In addition to the EAP, Nuvation Bio continues to engage with healthcare professionals and patient advocacy groups to ensure that the needs of patients with ROS1+ NSCLC are prioritized. This strategic initiative not only enhances the company's profile within the oncology field but also reflects a broader trend towards patient-centered care in biopharmaceutical innovation. The ongoing dialogue with stakeholders is vital as Nuvation Bio works towards bringing taletrectinib to the market and addressing the significant challenges faced by these patients.